• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "April, 2016"
 Nascent Biotech Announces Orphan Drug Designation for Pancreatic Cancer
 0
By Nascent Biotech
In Corporate News, Science News
Posted April 25, 2016

Nascent Biotech Announces Orphan Drug Designation for Pancreatic Cancer

Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA [...]

READ MORE
 Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors
 0
By Nascent Biotech
In Corporate News
Posted April 14, 2016

Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors

Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.